Company profile
Inhibikase Therapeutics, Inc.
NASDAQ: IKT · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
43DFH 67DQ 23GM 8SS 48
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$48.3M
Employees
35
as of 2026-08-13
Market cap
$316.9M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$48.3M-$48.3M2025
Operating income-$52.0M-$52.0M2025
Total assets$181.2M$181.2M2025
Liabilities$8.3M$8.3M2025
Equity$172.9M$172.9M2025
Revenue trend
FY2021 – FY2024 · USD
FY21
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Inhibikase Therapeutics, Inc.’s revenue?
Inhibikase Therapeutics, Inc. booked $0 in FY2024 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Rocket Pharmaceuticals, Inc.53DPalisade Bio, Inc.71BSAB Biotherapeutics, Inc.52DZentalis Pharmaceuticals, Inc.40DEledon Pharmaceuticals, Inc.39DFulcrum Therapeutics, Inc.58CNeighbors
New Castle →Key facts
CEOMark T. Iwicki
SectorHealthcare
IndustryBiotechnology
HeadquartersWilmington, DE
ExchangeNASDAQ: IKT
Employees35
IPO date2020-12-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.